Novel Assessment of Synaptic Density in Progressive MS
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The investigators propose to use the novel SV2a-PET ligand, [F-18]SDM-8 to assess synaptic
density in progressive MS (including primary progressive multiple sclerosis (PPMS) and
secondary progressive multiple sclerosis (SPMS)) as compared to relapsing-remitting multiple
sclerosis (RRMS) patients and healthy controls, given its improved imaging characteristics
and potential for large scale applicability.
The specific aims of the study are:
Aim 1: To compare the cortical and subcortical grey matter synaptic density in progressive MS
patients, patients with relapsing-remitting MS, and healthy subjects, using a novel [F-18]
labeled synaptic density PET ligand, [F-18]SDM8, also known as [F-18]SynvesT-1.
Aim 2: To compare the relationship of synaptic density PET and standard 3T MRI measures
including global and regional brain atrophy and lesion load with clinical measures of
physical disability, cognitive impairment, fatigue and depression in MS patients.
Aim 3: To assess the relationship of synaptic density PET with serum neurofilament light
chain (NfL) and with serum measurements of inflammatory markers, IL-1β, TNF-α, IL-6, MCP-1
(Monocyte Chemoattractant Protein-1) and MIF-1 (Macrophage Migration Inhibitory Factor-1).